National Dentex Corporation (NASDAQ: NADX), One of the largest owner/operators of dental laboratories in North America, today announced that it has extended an agreement for exclusive manufacturing and distribution rights to fabricate and market the lab version of the NTI-tss. The contract runs through 2023 and also grants exclusive use of the trademarked name.

The NTI-tss, a small, custom-made dental mouthpiece is FDA approved for the prevention and treatment of migraine pain. The product name refers to nighttime tension suppression system.

The device offers an affordable, non-pharmaceutical option to an estimated 28 million Americans suffering from various forms of migraine headache. In clinical trials reviewed by the FDA in 2001, 82% of medically diagnosed migraine sufferers using the NTI-tss had a 77% average reduction of migraine pain attacks within the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%.

The NTI-tss device was developed and patented by entrepreneurial dentist, James Boyd, DDS. Having suffered chronic, all-day headaches and frequent migraine attacks for 12 years, Dr. Boyd developed the NTI therapeutic protocol to rid him of his pain. He is now an associate with The Headache Center Neurology Clinic in Encinitas, CA.

National Dentex owned Keller Laboratory has been the exclusive U.S. manufacturer of the NTI-tss for the past 6 years. During that time unit sales of the appliance have grown at an average annual rate of more than 30%.

David Brown, President & CEO, commented: “We believe the NTI to be an exceptional health care product. Our agreement with Dr. Boyd not only enables us to continue to support and provide relief to people who suffer from debilitating migraines, but to expand that support throughout our entire laboratory system of 47 locations across the United States.”

About National Dentex

National Dentex Corporation serves an active customer base of over 24,000 dentists through forty-one full service and seven branch dental laboratories located in 31 U.S. states and one Canadian province. National Dentex’s dental laboratories provide a full range of custom-made dental prosthetic appliances, including dentures, crowns and fixed bridges, and other dental specialties.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding our marketplace competitiveness, opportunities, and expected courses of action, that are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which National Dentex operates. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors that may affect future operating results include the timing, duration and effects of adverse changes in overall economic conditions and other developments that directly or indirectly affect consumer decisions as to whether and when to have dental procedures performed; governmental regulation of health care; trends in the dental industry towards managed care; increases in labor, benefits and material costs; product development risks; technological innovations; competition from other dental laboratories, including increased competition from dental laboratories located in foreign countries such as China: National Dentex’s ability to attract, retain and motivate qualified personnel; any impairment in the carrying value of goodwill or other acquired intangibles; compliance with evolving federal securities, accounting, and marketplace rules and regulations applicable to publicly-traded companies on the Nasdaq National Market; and other risks indicated from time to time in National Dentex’s filings with the Securities and Exchange Commission, particularly under Item 1A, “Risk Factors” of National Dentex’s most recently filed Annual Report on Form 10-K.